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Abstract 
 
Background: Clozapine is the most effective antipsychotic for treatment resistant 
schizophrenia but is considered a high risk drug due to the risk of side effects.  
Clozapine incidents are the second most frequently reported by mental health 
services to the National Reporting and Learning System (NRLS), which uses reports 
for learning.  
 
Aim: To review and analyse clozapine errors reported to the NRLS. 
 
Methods: Following extraction of one year of clozapine incidents from the NRLS, a 
qualitative analysis (thematic analysis and re-classification) and quantitative analysis 
was undertaken.  
 
Results: “Issues with stock/supply/ordering” was the most common theme derived 
from the qualitative thematic analysis (n=338), followed by wrong 
dose/strength/frequency (n=221) and medication omissions (n=202). Most errors 
occurred in the “Administration/supply” medication stage. Over half of reported 
clozapine incidents involved people 26-55 years old (n=830) and 82% of errors were 
reported by mental health services (n=1270). Only 1.5% of reports were classed as 
moderate/severe harm.  
 
Conclusion: Issues with availability, stock and supply was found to be the most 
common cause. This usually entailed a lack of stock to fulfil a patient’s dose/supply. 
Such incidents could potentially be reduced by improved management of the supply 
process, and liaison between pharmacy and clinical staff. The implementation of 
emergency drug cupboards at the discretion of an on-call pharmacist may prove to a 
preventative measure for such errors. Despite the potential adverse effects 
associated with clozapine, very few incidents led to moderate/severe harm. 
Encouragement of NRLS reporting is recommended, for incidents of all degrees of 
harm.  
  
Introduction  
 
A medication error is defined as a failure in the medication process that causes, or 
has the potential to cause, harm1,2. Medication related harm accounts for up to 6.5% 
of unplanned admissions3, costing the National Health Service (NHS) approximately 
£774million annually4. Consequently, it is imperative to report medication errors so 
that healthcare providers can learn from incidents. 
 
As part of its patient safety function, the NHS collates and manages a central 
database of safety incidents, via its NHS Improvement body5. The National 
Reporting and Learning System (NRLS) is the database which records information 
about incidents which can be submitted electronically through local systems or 
online6,7. Incident data is then analysed with clinical input and reports are published 
on the NHS Improvement website. Patient safety alerts may be issued if significant 
trends are identified nationally.5  
 
The atypical antipsychotic clozapine8 was found to be the second most frequently 
reported medication by mental health services to the NRLS, between 01/01/07 to 
31/12/072. Clozapine has been shown to have greater efficacy than other 
antipsychotics in treatment resistant schizophrenia8 and it reduces mortality through 
a reduction of suicide rates9. The National Institute for Health and Care Excellence 
(NICE) guidelines for England/Wales place clozapine as third line therapy in patients 
who have been unresponsive or intolerant to two other antipsychotics – at least one 
atypical10. In the USA and Europe, clozapine is similarly used in treatment-resistant 
schizophrenia11,12,13.   
 
Clozapine has a range of side effects14. To reduce the severity and risk of adverse 
events, patients must adhere to a strict gradual titration (starting at 12.5mg). This 
however, must be balanced with the delay to therapeutic response which may pose 
a risk to the patient and/or others. If clozapine is missed for greater than 48 hours, 
the dose must be re-titrated and monitoring must return to a weekly cycle15. This has 
a negative impact on the patient and can prove to be a preventable burden to NHS 
resources. 
 
Clozapine’s potentially fatal haematological side effects (neutropenia and 
agranulocytosis) demonstrates the importance of regular blood monitoring of white 
cell counts, neutrophils and platelets. Blood monitoring is conducted every week, two 
weeks or month based on treatment duration14,15,16.  
 
Clozapine is a high risk drug and is therefore usually initiated and prescribed by a 
consultant psychiatrist in secondary care. Once stable, GPs may prescribe clozapine 
through a shared-care protocol (although uncommon)17.  
 
It has been highlighted that antipsychotics account for the majority of harmful 
medication errors reported in mental health18. Despite this, coupled with the 
concerns around clozapine’s safety profile19 and the high frequency of errors 
reported2, clozapine incidents have not been analysed using qualitative methods. 
Consequently, this study is the first in-depth analysis of clozapine incidents reported 
to the NRLS. The aim of this study was to analyse clozapine associated NRLS errors 
in order to identify any significant error types and themes. The objectives were to 
collect NRLS clozapine data; analyse the data qualitatively through a thematic 
analysis and re-categorisation; analyse the data quantitatively; briefly examine 
reporting quality; and identify possible solutions to common clozapine errors. 
 
 
Method 
 
Following NRLS approval, one year of reported clozapine incidents were extracted 
from the database by DG using “SAS Enterprise Guide” 20. Terms searched were 
clozapine and its brand names (including misspells).  
 
Reporting to the NRLS  
 
Incidents can be reported to the NRLS via local trust reporting systems or the online 
form (https://report.nrls.nhs.uk/nrlsreporting/).  
 
When reporting an incident to the NRLS, there are three fields that allow the reporter 
to transcribe incident details (free text descriptions): ‘Description of what happened’, 
‘Actions preventing reoccurrence’ and ‘Apparent causes’. There are also NRLS fields 
with drop down menus (as shown in Figure 1), from which a single option can be 
chosen. These fields include the medication process stage, medication error 
category, age range, degree of harm and care setting of occurrence. 
 
 
 
 
 
 
 
Qualitative analysis – thematic analysis  
 
From the incidents extracted, the three free text fields were analysed (as one entity) 
for the thematic analysis (Figure 2). Firstly, descriptions were read and irrelevant 
reports/ duplicates were discarded. Reports were considered if they met the 
medication error criteria (i.e. a failure in the medication process). Medication process 
stages include prescribing, dispensing, preparing, administering, monitoring or 
advising2,4. Incidents were considered irrelevant if the error was not directly 
associated with clozapine – e.g. clozapine patient missed Kwells dose (for clozapine-
induced hypersalivation).  
Figure 1: Reporting page for the NRLS 
(https://report.nrls.nhs.uk/nrlsreporting/) 
 
	
For incidents relevant to clozapine, summaries were produced for each. Each 
summary was then condensed and broken down further to produce “themes” - in 
some cases up to four themes were relevant to each incident. After all themes were 
constructed, grouped and finalised, the occurrence of each theme was counted 
using a Pivot Table (Microsoft Excel).   
 
Themes were either influenced by existing NRLS categories or were constructed 
based on the incident summary. For example, the three NRLS categories “Wrong 
frequency”, “Wrong quantity” and “Wrong/ unclear dose or strength” could overlap – 
administering 2 tablets instead of 1 could be categorised as “Wrong quantity” or 
“Wrong/unclear dose or strength”. Consequently, “Wrong dose/strength/frequency” 
was developed as a theme. It was chosen when the wrong quantity, frequency or 
strength of tablets led to, or could have potentially led to, the wrong dose. “Wrong 
quantity” was generated as a separate theme where the patient received 28 tablets 
instead of 14 for example, but did not take the wrong dose.  
 
 
 
 
Qualitative analysis – re-classification 
 
It was agreed amongst the authors that the medication process stage and 
medication error category fields were likely to be most subjective. Therefore, for all 
incidents, both of these fields were re-classified using the NRLS website for 
guidance(https://www.eforms.nrls.nhs.uk/staffreport/help/AC/Dataset_Question_Refe
rences/Medicine_incident_details/MD02.htm).  
 
The purpose of re-classification was to have an accurate and consistent 
representation of what happened in reported incidents.  
 
The medication process stage was classified based on which stage of the 
medication process the error took place, not which stage it was found. If none were 
suitable, such as self-administration errors, then “Other” was the option chosen.  
 
Validation 
 
The primary author (pharmacist), was responsible for theming and re-classifying all 
incidents for consistency; 10% of these incidents were validated by a chief 
pharmacist.  Other authors from NHS Improvement were consulted on occasions 
where there was a lack of clarity.  
 
 
 
Figure 2: Steps taken for the qualitative analysis 
	
Quantitative analysis of incidents 
 
For all incidents, the following fields were extracted and quantified using a Pivot 
Table: age range, degree of harm, care setting of occurrence, medication process 
stage and medication error category. The outcomes from the thematic analysis and 
re-classification were also quantified using the same method.  
 
 
Results 
 
A total of 1,667 reports were yielded from the NRLS search. From these, 1,548 
reports were found to be true clozapine errors following the exclusion of duplicates 
and irrelevant reports.  
 
Thematic analysis 
 
In total, 1,904 themes were produced for 1,548 incidents. The ten most common 
themes identified in this analysis are listed in Table 1 and accounted for over two 
thirds of incidents reported. The most common themes discovered were “Issues with 
medication stock/supply/ordering”, “Wrong dose/strength/frequency” and 
“Omission…”, collectively themed for almost half of all reports (n=761). Examples of 
these themes are listed in Table 2.  
 
 
 
 
 
  
Table 1: The 10 most common themes derived from the free text 
 
	 	Table	2:	Free	text	report	examples	by	theme	
Reports	are	mostly	unedited	except	where	irrelevant	information,	dates	&	names	have	been	removed	
Theme	coded	 Incident	free	text	examples	
“Issues	with	
stock/supply/ordering”	
Delivery	of	clozapine	medication	was	overlooked	on	Friday	
[date].	Member	of	staff	realised	on	sunday	night,	unable	to	
get	access	to	[name]	centre	to	enable	delivery	of	medication.	
Clozapine	evening	dose	omitted	due	to	lack	of	his	
medication	on	the	ward.	
“Wrong	
dose/strength/frequency”		
Patient	was	mistakenly	given	12.5	mg	of	Clozapine	at	16:00.	
She	was	on	titrating	regime	of	Clozapine.	She	had	150mg	
Clozapine	in	the	morning	and	was	due	to	have	150mg	at	
night.	Dr	was	informed	and	reduced	evening	dose	to	
137.5mg.	
A	service	user	was	inadvertently	given	300mg	of	clozapine	
instead	of	225mg	as	a	100mg	strip	was	in	the	25mg	box	and	
an	extra	100mg	tablet	ended	up	being	dispensed	into	the	
meds	pot	instead	of	a	25mg	tablet.		
On	[date],	the	pre	-	admission	dose	of	clozapine	(50mg	OM	
and	100mg	ON)	was	prescribed	by	a	junior	doctor	under	the	
Gastro	consultant	advice	when	its	use	has	been	discontinued	
for	more	than	48	hours...	Clozapine	is	normally	re-titrated	
from	lower	doses,	when	the	omitted	duration	is	longer	than	
48	hours...		
Omission	–	medicine	not	
administered/	dispensed	/	
supplied	/	prescribed	
Staff	Nurse	failed	to	administer	clozapine	to	patient.	
I	was	administering	night	medication	from	his	blister	pack	
when	I	noticed	that	it	was	short	of	the	prescribed	
medication.	Missing	from	the	blister	pack	were	clozapine,	
simvastatin	and	propranolol.		
Patient	had	been	admitted	to	hospital	on	26th	[date].	A	
pharmacist	saw	the	patient	on	the	ward	on	the	27th	[date]	
and	noted	that	the	patient	was	on	clozapine	(200mg,	mane	
and	400mg	nocte).	The	pharmacist	asked	the	care	home	to	
bring	in	the	clozapine	as	it	is	not	something	we	keep	and	
documented	in	the	notes	that	it	needed	prescribing.	The	
medication	was	bought	in	but	was	not	prescribed.	The	
patient	therefore	missed	8	doses	of	clozapine	by	the	time	I	
saw	him	on	3rd	[date].	
	
Table 2: Free text report examples by theme 
	
Medication process stage (re-classified) 
 
the re-classification found that most errors occurred during the “Administration / 
supply of a medicine…” (59.8%, n=926) and “Preparation… / dispensing…” (16.5%, 
n=255) medication stages, followed by “Prescribing” (13.2%, n=255). 
 
 
 
Medication error category (re-classified) 
 
The three most common re-classified categories, as displayed in Table 4, were 
“Other” (30.8%, n=477), “Omitted medicine/ingredient” (27.9%, n=432) and 
“Wrong/unclear dose or strength” (18.6%, n=288). A significant proportion of 
incidents categorised as “Other” (149 out of 477 reports; 31%) involved problems 
with medicines supply/stock/ordering, for which no NRLS option is available.  
 
 
 
Table 3: Medication Process Stages (Re-classified) 
 
Table 4: Medication Error Category (Re-classified) 
 
Degree of harm 
 
The quantitative analysis for the degree of harm, Table 5, found that no or low harm 
was reported for 1,526 incidents (from a total of 1,548). No reports led to death and 
1.5% of incidents were reported as resulting in moderate or severe harm (n=22).  
 
The incident reported as severe harm (n=1) was found to be misclassified, based on 
the free text provided. Table 6 below highlights the moderate harm incident types by 
care setting.  
 
 
 
 
  
Table 5: Degree of Harm 
 
Table 6: Moderate harm medication error categories by care setting 
 
Age range 
 
As displayed in Table 7, the majority of incidents involved people between the age of 
18-65 (69%; n=1063), with 26-35 years (20%; n=314) being the most common age 
bracket reported. Six incidents were reported as involving children between the age 
of 0-1 years. However, the free text for these incidents indicated that none of these 
actually involved children and were therefore data entry errors by reporters. A 
quarter of incidents did not have an age range reported (n=386). 
 
 
 
 
  
Table 7: Age Range 
 
Care setting 
 
Table 8 illustrates that the majority of reports (82%; n=1270) are from mental health 
services, with very few (approx. 3%; n=47) being reported by primary care and 
community settings.  
 
Incidents reported by acute / general hospitals (13%; n=203) have been categorised 
by theme in Table 9.  
   
 
  
Table 9: Most common themes derived from the free text reported by Acute / 
General Hospital settings 
	
Table 8: Incidents by Care Setting 
	
Discussion 
 
This analysis identified common error types and themes, through a combination of 
quantitative and qualitative methods. Those results of particular interest have been 
discussed below under the relevant sub-headings. 
 
Thematic analysis 
 
Issues with medication supply/stock/ordering was identified as the most common 
cause and theme of incidents; a similar finding to thematic analyses based on other 
medications2,4,21,22.  
 
This theme may have been the most common as there are additional steps, such as 
regular blood tests, required to permit the supply of clozapine, compared to other 
medications. Therefore, overall, the increased need to dispense clozapine, and the 
impact of this on its supply, could explain the relatively high prevalence of errors 
associated with supply15,23.  
 
Another factor for the high occurrence of this theme is that clozapine is only available 
on a patient named basis24 and so its availability as stock is limited. In multiple 
incidents, low or no clozapine stock levels, led to patients not getting their (full) 
clozapine dose. Some cases involved borrowing another patient’s clozapine and 
replenishing it later; however, most trust policies advise against this25,26,27.  
 
Medication should be ordered on time to reduce clozapine errors related to its 
supply, stock and ordering. Expanding limits on clozapine supplies in emergency 
drug cupboards, with some type of national guidance, may reduce such errors; this 
could be at the discretion of the on-call pharmacist to provide some control 
mechanism. Further work is required to verify the feasibility of this recommendation.  
 
Wrong dose/strength/frequency was the second most common theme. This included 
when clozapine was given at its original dose instead of being re-titrated (after being 
missed for >48 hours). In many cases where a higher dose was taken, blood tests 
and physical observations were required; this is associated with staff and laboratory 
costs28.  
 
The third most common theme was missed doses. If patients miss clozapine for 
more than 48 hours, the dose should be re-titrated from 12.5mg from an original 
dose as high as 900mg14,16. Therefore, an omission error puts the patient at risk of 
two additional errors. The first is that a substantial dose reduction could put the 
patient at a risk of relapse, and thus refractory psychosis, if they have not already 
relapsed during the no clozapine period29. Second, there is a possibility for the 
clozapine to be administered at the full dose instead of the re-titration dose, 
increasing the risk of adverse events15.  
In an attempt to reduce missed doses, primary and secondary care must work 
together more effectively. For example, mental health services should notify GPs if a 
patient has been initiated on clozapine and give regular updates regarding dose 
changes. This should then be documented on the patient’s GP records. As a result, 
for any subsequent acute hospital admission or mental health admission in a 
different trust, medication details would be available on the Summary Care Record 
(SCR). This allows access to the patient’s updated medication information, improving 
the safety and quality of care provided30. This would also reduce errors due to 
communication issues (n=133) between primary and secondary care. A 
recommendation to reduce errors in acute settings is for clozapine guidance to be 
issued to acute/general hospitals31. 
Medication process stage 
 
Similar to “Safety in Doses” 2,4, the “Administration/supply…” stage was found to be 
the most commonly reported medication stage. Using the Swiss Cheese Model, 
there may be fewer layers of defence when progressing from “Prescribing” (n=204) 
to “Preparation…/ dispensing…” (n=255) to “Administration/supply…” (n=926), and 
subsequently more scope for errors32. Also, administration is a more frequent 
process2 and the supply of clozapine is more frequent than most other medications, 
especially in the initial stages.  
 
Many incidents with “Other” selected were associated with self-administration. This 
coincides with the NRLS “Safety in Doses” paper which acknowledges that the 
selection of the “Other” category could be minimised by the introduction of a self-
administration field2. More work is needed to identify the causes of these self-
administration errors. 
 
Medication error category 
 
The most common medication error option selected to describe the incidents, by 
reporters and KD, was “Other”. The addition of the option "issues with 
supply/stock/ordering” would have reduced “Other” reports significantly, as 
discovered in other analyses too2,4,21,22.  
 
Age range 
 
Clozapine is primarily used in a young to middle aged population33 and most 
incidents involved people who were reported as 26-55 years (Table 7).  
 
The lack of reports in the upper age ranges (66+) may be due to the reduced life 
expectancy in people with schizophrenia, in whom mortality rates are 2-3 times 
higher compared to the general population; this corresponds to a 10-25 year lower 
life expectancy34. There is an increased risk of clozapine-related adverse events in 
the elderly, particularly anticholinergic2 and haematological side effects; the risk of 
agranulocytosis increases four to five fold35. This side-effect burden could explain 
the limited use of clozapine in older people36 and therefore the lower levels of 
reporting seen.  
 
Six incidents were reported for children under the age of 1, however upon reviewing, 
all six were data entry errors. Schizophrenia is rarely diagnosed in childhood due to 
the lack of diagnostic clarity at young ages37.  
 
Degree of harm  
 
Clozapine has potentially fatal adverse effects such as myocarditis, constipation and 
agranulocytosis38,39,40,41. Yet, no reports in this analysis were reported as severe or 
leading to death. Overall, only 0.8% of all incidents were reported as an Adverse 
Drug Reaction (ADR), possibly due to most ADRs being reported directly to 
medication manufacturers, license holders, and through the Yellow Card Scheme22. 
 
Limitations  
 
The results of this analysis cannot be used to imply the strict prevalence of any one 
category of error. Instead, it suggests that such errors exist, have been reported and 
that certain incidents have been reported more frequently than others.    
However, under-reporting is common, with just one in five NHS incidents being 
reported6,42,43. Generally, primary care settings report significantly less than 
secondary care2,4, although in this instance, secondary care tends to support 
clozapine management.  
 
The NRLS has been criticised for collecting insignificant “wide and shallow” data as 
opposed to “narrow and deep”. “Narrow and deep” data collection would result in 
detailed incidents which are less common and more serious in harm44. To the 
contrary, only 1.5% of reports led to moderate or serious harm. This, however, is 
dependent on what trusts and individuals decide to report. Increased awareness of 
the NRLS could improve this.  
 
A drawback of NRLS data is that it does not record gender nor ethnicity, thus 
providing limited information on patient demographics. Also, the NRLS only allows a 
single option to be chosen per field. However, on numerous occasions, multiple 
options were suitable. This led to subjectivity, as to which option was most 
representative of the incident. The addition of a functionality that allows multiple 
selections would improve the accuracy of reporting. 
The subjectivity of coding and re-classification demonstrates the limitation of the 
qualitative methodology used45.  
  
Quality of reporting 
 
The quality of reporting was studied by comparing how similarly categories were 
selected by reporters vs during re-classification. Supplementary Table 10 illustrates 
this comparison for the medication stage process; e.g. “Administration / supply…” 
was selected by reporters 715 times compared to 926 times during re-classification 
(agreed on 608 incidents). This comparison is similarly displayed in Supplementary 
Table 11 for the medication error category field.  
 
Another limitation of the reports received was the poor clinical detail and lack of root 
causation.  For the “Actions preventing reoccurrence” field, 43% of the column was 
filled out (n=662); with a median of 19 words per report (Range: 0 – 494 words). The 
“Apparent Causes” field was only completed for a third of reports, with a median of 
14 words per entry (Range: 0 – 391 words). Apparent causes, however, were 
commonly seen under the “Description of what happened” field. As a result, all three 
free text descriptions were analysed as one entity.   
 
Age ranges were poorly reported with missing age data for 25% of incidents (n=386). 
Although a qualitative analysis was not comprehensively performed for the age 
range, incidents involving children <1 year were reviewed and found to be 
categorised incorrectly.  
 
Conclusion 
This paper reports the first analysis of clozapine incidents reported to the NRLS. It 
has identified the most commonly reported categories for a range of fields, with the 
key cause of errors identified as issues with supply, stock and ordering. By having 
the availability of more clozapine in the emergency drug cupboard and better 
ordering procedures, it is possible for incidents to be reduced. Emergency drug 
cupboards could be implemented and tested in practice to see if errors decrease on 
a local level.   
 
Many errors related to wrong/unclear doses and omissions (second and third most 
common themes), particularly in acute and general hospital settings, could 
potentially be reduced by regularly updating the patient’s SCR. This is achievable 
through improved communication and updates between mental health services and 
primary care. 
 
Reporting medication errors provides invaluable information for learning and service 
improvement. It is therefore recommended that further research into the quality of 
NRLS data reported is explored in more depth; with possible solutions to improve 
reporting accuracy and reduce subjectivity/inconsistencies. Reporting incidents of all 
severities of harm should be encouraged so that analyses are comprehensive.    
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